Oguma Junya, Ozawa Soji, Sakakibara Terue, Kajiwara Hiroshi, Nakamura Naoya, Makuuchi Hiroyasu
Department of Gastroenterological Surgery Tokai University School of Medicine Isehara Japan.
Department of Pathology Tokai University School of Medicine Isehara Japan.
Ann Gastroenterol Surg. 2020 Dec 14;5(2):194-203. doi: 10.1002/ags3.12415. eCollection 2021 Mar.
In the present study, we investigated the relationship between the expressions of two cancer testis antigens (CTA), LY6K (lymphocyte antigen 6 complex locus K) and CDCA1 (cell division cycle associated 1), in esophageal squamous cell carcinoma (ESCC) tumors and the long-term outcomes of patients with ESCC to clarify the clinical significance of LY6K and CDCA1 expression in ESCC tumors.
A total of 175 patients with thoracic ESCC who had undergone a thoracic esophagectomy with three-field lymphadenectomy without neoadjuvant therapy were retrospectively reviewed in this study. LY6K and CDCA1 expressions were evaluated in tumor tissues using immunohistochemical (IH) staining.
Median patient age was 63 years; 159 patients (90.9%) were men. Ninety-four patients (55.3%) were LY6K-positive, and 85 patients (48.6%) were CDCA1-positive. The LY6K-positive group had a significantly worse overall survival (OS) than the LY6K-negative group ( = 0.012), and the CDCA1-positive group had a significantly worse OS than the CDCA1-negative group ( = 0.010). A multivariate analysis suggested that pathological N stage, venous invasion, LK6Y-positive and CDCA1-positive were independent prognostic factors. The patients were classified into four groups according to the staining pattern combinations of the two CTA. The LY6K-positive and CDCA1-positive group was found to have a significantly poorer outcome than the other groups.
ESCC patients with a combination of LY6K and CDCA1 expression in their tumor tissues had a worse prognosis than all the other ESCC patients and it was an independent factor associated with prognosis for patients with ESCC.
在本研究中，我们调查了两种癌睾丸抗原（CTA），即淋巴细胞抗原6复合体基因座K（LY6K）和细胞分裂周期相关蛋白1（CDCA1）在食管鳞状细胞癌（ESCC）肿瘤中的表达与ESCC患者长期预后之间的关系，以阐明LY6K和CDCA1表达在ESCC肿瘤中的临床意义。
本研究回顾性分析了175例接受了胸段食管切除术及三野淋巴结清扫且未接受新辅助治疗的胸段ESCC患者。采用免疫组织化学（IH）染色评估肿瘤组织中LY6K和CDCA1的表达。
患者中位年龄为63岁；159例（90.9%）为男性。94例（55.3%）患者LY6K呈阳性，85例（48.6%）患者CDCA1呈阳性。LY6K阳性组的总生存期（OS）显著低于LY6K阴性组（P = 0.012），CDCA1阳性组的OS显著低于CDCA1阴性组（P = 0.010）。多因素分析表明，病理N分期、静脉侵犯、LY6K阳性和CDCA1阳性是独立的预后因素。根据两种CTA的染色模式组合将患者分为四组。发现LY6K阳性和CDCA1阳性组的预后明显比其他组差。
肿瘤组织中同时表达LY6K和CDCA1的ESCC患者的预后比其他所有ESCC患者更差，这是ESCC患者预后的一个独立相关因素。
